Rebouissou et al. showed that altered β-catenin activity was attributed to the position of the affected amino acid, where a cancer-specific phenotype was associated with mutations within the beta-transducin repeat-containing protein (β-Trcp) binding site [30]. Here, BTRC is linked to cancer.